Victory Square Reports Q1 2026 Financial Results and Provides Portfolio Update
Summary
Victory Square Technologies reported strong Q1 2026 results, with revenue rising to $24.9 million, net income reaching $3.9 million, and cash and marketable securities increasing to about $31 million. The company highlighted progress across its portfolio, especially Hydreight Technologies, which grew its VSDHOne platform to more than 12,000 licenses and completed a $15 million financing. Insu Therapeutics advanced its semaglutide delivery research with Phase I preclinical completion and ethics approval for Phase II studies. Pawsible Ventures also launched new pet-health initiatives, including a venture platform, fund, studio, incubator, and advisory board. Victory Square said it will keep focusing on platform expansion, portfolio support, and monetization opportunities.
